Who makes XOMA 358 single dose level C?

XOMA 358 single dose level C is developed by XOMA (US) LLC.

What development phase is XOMA 358 single dose level C in?

XOMA 358 single dose level C is in Phase 2.

Last reviewed 2026-05-13 · How we verify

XOMA 358 single dose level C

XOMA (US) LLC · Phase 2 active Small molecule

At a glance

Generic name	XOMA 358 single dose level C
Sponsor	XOMA (US) LLC
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery (PHASE2)
A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

XOMA 358 single dose level C CI brief — competitive landscape report
XOMA 358 single dose level C updates RSS · CI watch RSS
XOMA (US) LLC portfolio CI